Mackenzie Financial Corp Makes New Investment in OraSure Technologies, Inc. (NASDAQ:OSUR)

Mackenzie Financial Corp acquired a new stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 27,964 shares of the medical instruments supplier’s stock, valued at approximately $229,000.

Several other hedge funds have also recently made changes to their positions in OSUR. Tocqueville Asset Management L.P. purchased a new stake in OraSure Technologies during the 3rd quarter valued at about $75,000. Pathstone Family Office LLC purchased a new stake in OraSure Technologies in the third quarter valued at approximately $80,000. Diversified Trust Co increased its holdings in OraSure Technologies by 17.7% in the 4th quarter. Diversified Trust Co now owns 16,031 shares of the medical instruments supplier’s stock worth $131,000 after buying an additional 2,406 shares during the period. Raymond James & Associates purchased a new position in OraSure Technologies during the 4th quarter worth approximately $133,000. Finally, Simplicity Solutions LLC lifted its stake in OraSure Technologies by 146.4% during the 3rd quarter. Simplicity Solutions LLC now owns 40,036 shares of the medical instruments supplier’s stock valued at $237,000 after acquiring an additional 23,789 shares during the period. 93.50% of the stock is owned by institutional investors and hedge funds.

OraSure Technologies Stock Up 1.1 %

Shares of OraSure Technologies stock opened at $5.32 on Monday. The firm has a market cap of $407.03 million, a PE ratio of 7.39 and a beta of 0.15. The business has a 50-day moving average price of $6.33 and a 200 day moving average price of $6.81. OraSure Technologies, Inc. has a twelve month low of $4.38 and a twelve month high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.09. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The business had revenue of $75.88 million during the quarter, compared to the consensus estimate of $74.13 million. During the same period in the prior year, the company posted $0.21 EPS. The business’s quarterly revenue was down 38.3% on a year-over-year basis. On average, sell-side analysts expect that OraSure Technologies, Inc. will post -0.11 EPS for the current year.

Analysts Set New Price Targets

OSUR has been the subject of several recent research reports. StockNews.com cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, April 23rd. Evercore ISI reduced their price objective on OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a research note on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, OraSure Technologies presently has a consensus rating of “Hold” and a consensus price target of $6.38.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.